Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer.
Saved in:
| Title: | Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer. |
|---|---|
| Authors: | Lee W; The CHOICE Institute, School of Pharmacy, University of Washington, Seattle, WA, USA., Wong WB; Genentech Inc., South San Francisco, CA, USA., Kowal S; Genentech Inc., South San Francisco, CA, USA., Garrison LP Jr; The CHOICE Institute, School of Pharmacy, University of Washington, Seattle, WA, USA., Veenstra DL; The CHOICE Institute, School of Pharmacy, University of Washington, Seattle, WA, USA., Li M; Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. mli14@mdanderson.org. |
| Source: | PharmacoEconomics [Pharmacoeconomics] 2022 Jun; Vol. 40 (6), pp. 623-631. Date of Electronic Publication: 2022 May 09. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9212404 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-2027 (Electronic) Linking ISSN: 11707690 NLM ISO Abbreviation: Pharmacoeconomics |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1179-2027 |
|---|---|
| DOI: | 10.1007/s40273-022-01147-5 |
